Literature DB >> 3700343

Combination therapy with lecithin and ergoloid mesylates for Alzheimer's disease.

M A Jenike, M S Albert, H Heller, S LoCastro, J Gunther.   

Abstract

A 10-week placebo-controlled double-blind crossover protocol of combination therapy with lecithin and ergoloid mesylates was conducted in seven patients with presenile and senile dementia, Alzheimer's type. The patients' abilities to detect spatial arrangements, to recognize faces, and to identify new words on the Delayed Recognition Span Test were not significantly improved. Dementia Rating Scale scores before treatment were not significantly different from those after treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3700343

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  3 in total

Review 1.  Neuropathobiology of senile dementia and mechanism of action of nootropic drugs.

Authors:  O Benesová
Journal:  Drugs Aging       Date:  1994-04       Impact factor: 3.923

Review 2.  Recent advances in geriatric psychopharmacology.

Authors:  C A Naranjo; N Herrmann; N Mittmann; K E Bremner
Journal:  Drugs Aging       Date:  1995-09       Impact factor: 3.923

3.  A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease.

Authors:  Jason A Bailey; Debomoy K Lahiri
Journal:  J Neurochem       Date:  2009-11-11       Impact factor: 5.372

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.